Agree, BARDA will distort % revenue increases also as it is likely topping out at around $1/month so won't be much (if any) growth from BARDA revenue. Think BARDA reimbursement includes all (or majority) of costs associated with trial. Pure sales best indicator.
Ann: FY24 Trading Result (unaudited), page-171
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
0.020(0.78%) |
Mkt cap ! $1.780B | |||
| Open | High | Low | Value | Volume |
| $2.61 | $2.63 | $2.56 | $2.465M | 952.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10700 | $2.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.58 | 24502 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |